Instead, we implemented the prevalent new-user cohort design to include a board spectrum of T2D patients being treated with basal insulin and with or without baseline vascular complications, which ensured comprehensive assessment and enhanced the external validity of the study results to the real-world diverse T2D population requiring basal insulin therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.